Skip to main content
Caplight Logo









AGS Therapeutics

AGS Therapeutics

Private
ParisHealthcare & Life Scienceshttps://www.ags-tx.com/

Last Round

Accelerator

May 30, 2023

Company Overview

AGS Therapeutics is a biotechnology company that utilizes the natural machinery of microalgae to develop therapeutics such as mRNA, RNAi, proteins and peptides, delivered by microalgae extracellular vesicles.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

microalgae extracellular vesiclesMEVsdrug delivery platformextracellular vesiclesplant-derived exosomesalgae-based drug deliverymRNA deliverynon-viral vectorsiRNA deliveryLNP alternativeCDMO servicescontract development and manufacturingCDMObiomanufacturingoral drug deliveryophthalmic drug deliverygene therapy deliveryinflammatory bowel disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AGS Therapeutics Comparables

Compare AGS Therapeutics with similar companies based on industry and business-model similarity.

AGS Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ciloa
83%
Carmine Therapeutics
82%
Carus Bio
81%

AGS Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorMay 30, 2023
Series ADec 14, 2022
GrantJul 7, 2022
Pre SeedSep 7, 2021

AGS Therapeutics Investors

Notable investors and investment history

AGS Therapeutics investors
InvestorRounds
Government of FranceGrant
Spartners by Servier & BioLabsAccelerator
BpifranceGrant, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 30, 2023

    Received funding from Sparners by Servier & BioLabs.

  • Dec 14, 2022

    $32M round closed.

AGS Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AGS Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AGS Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Year Founded2020
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?